Capital Access Window

Ondine Biomedical Inc.

30 September 2026

 

This Announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation No. 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended. Upon the publication of this Announcement, this inside information is now considered to be in the public domain.

30 September 2026

ONDINE BIOMEDICAL INC.

(“Ondine Biomedical”, “Ondine”, or the “Company”)

Capital Access Window

Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies for the prevention and treatment of hospital infections, announces its intention to utilise AIM’s new Capital Access Window in connection with a proposed equity capital raise (the “Proposed Fundraise”). The Company also intends to launch a retail offer to enable retail investors to participate on the same terms.  

Proposed Fundraise

The Company is undertaking the Proposed Fundraise to provide funding towards publishing the full LANTERN trial analyses, advancing FDA engagement with the intention of submitting the NDA in mid-2027, as well as progressing commercial pilots and investing further in sales and marketing to broaden product deployments and deepen adoption in markets where Steriwave is already authorised, whilst also having access to additional working capital to fund growth. Finally, the Company plans to continue to enhance and strengthen the capabilities of the Board and its senior management team as the Company’s focus shifts to the critical next stage of its growth journey. 

Further details of the Proposed Fundraise will be announced in due course.

Capital Access Window

Following the updates to the AIM Rules for Companies announced in August 2026, the Company will enter a Capital Access Window with effect from 7.30 a.m. BST today. This is a voluntary temporary pause in the trading of the Company’s common shares on AIM, intended to make it easier to reach a broader range of investors and provide pricing stability during a fundraise. The Capital Access Window will remain in place until a further announcement is made detailing the results of the Proposed Fundraise.

This announcement does not constitute an offer of securities in any jurisdiction. The Proposed Fundraise, if implemented, will be the subject of further announcements, which will include its material terms and conditions.

Enquiries:

Ondine Biomedical Inc.	www.ondinebio.com
Carolyn Cross, CEO	[phone] or via 5654 & Company
Strand Hanson Limited (Nominated & Joint Financial Adviser)
James Harris, Richard Johnson, Imogen Ellis	[phone]
Peel Hunt LLP (Broker & Joint Financial Adviser)
James Steel, Dr. Chris Golden	[phone]
5654 & Company (Financial PR and IR Adviser)	[e-mail]
Matthew Neal, Chris Gardner, Melissa Gardiner, Lucy Featherstone	[phone] [phone] [phone]

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company focused on the development of light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those associated with multidrug-resistant organisms. Ondine's lead product, branded as Steriwave® outside the United States, is authorised for nasal decolonisation in Canada, the UK, and certain other international markets. The Company has a pipeline of additional photodisinfection products in various stages of development for application in areas including chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

Regulatory approvals, clearances and authorisations vary by jurisdiction, and indications, claims and availability may differ between markets. No statement in this announcement should be interpreted as representing approval, clearance, authorisation or availability in any jurisdiction, or for any use, where such status has not been granted.

U.S. Regulatory Status

Ondine’s nasal photodisinfection technology is not approved by FDA and is not commercially available for sale in the United States. In the United States, it is limited by federal law to investigational use only.

Forward-Looking Statements

This announcement contains forward-looking statements, including statements regarding clinical development, regulatory activities and approvals, commercial adoption, manufacturing and operational scale-up, future expenditure and potential indications for the Company’s technology. These statements are based on current expectations and are subject to risks and uncertainties that may cause actual results to differ materially.

Such risks include, among others, clinical trial outcomes and interpretation, completion of the full LANTERN analysis, regulatory engagement and decisions, the timing and acceptance of any NDA submission, the availability of financing and the Company's ability to continue as a going concern, manufacturing and supply-chain readiness, commercial adoption, reimbursement and market-access considerations, and competitive developments. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. The Company undertakes no obligation to update them except as required by applicable law, including the AIM Rules for Companies and UK Market Abuse Regulation.

 

END